Abstract
Autopsies of COVID-19 patients demonstrate the presence of SARS-CoV-2 in the brain endothelium, cerebrospinal fluid, glial cells, and neuronal tissue; while emerging clinical data suggest that ∼40% of COVID-19 patients develop neurological symptoms. We examined the effects of SARS-COV-2 RBD spike protein on blood brain barrier (BB) integrity, and on the expression of tight junction proteins (TJP) that maintain BBB permeability and function.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Paper Title
Journal
Date
